A Phase I Study of TL32711 In Combination with Gemcitabine in Patients with Advanced Solid Tumors

PrintE-mail
Title A Phase I Study of TL32711 In Combination with Gemcitabine in Patients with Advanced Solid Tumors
Contact AD
Principal Investigator Wen Wee Ma, MD
Study Number 210811
Phase1
Summary The purpose of this study is to determine the dose of TL32711 that is safe and tolerated when given with gemcitabine to patients with advanced cancer.
Eligibility

Inclusion:

  • Histologically or cytologically confirmed solid tumors that are advanced or metastatic that gemcitabine-based combination is considered standard therapy. 
  • Measurable disease. 
  • Consent to the use of their archival tumor tissue. 

Exclusion:

  • Patients who have received recent anti-cancer therapy. 
  • Patients who have undergone major surgery.
For more information about the clinical study go to Clinicaltrial.Gov